

Table S1. Supplementary information on the comparison between Lactoferrin and Placebo Groups

	Lactoferrin	Placebo	p
Demographic and clinical characteristics			
Maternal age in years, mean \pm SD	30.7 \pm 6. 9	30.0 \pm 6.6	0.450
Obstetric complications, n/total (%)	87/95 (92.6)	88/94 (93.6)	0.782
Preeclampsia or eclampsia	18/95 (19.0)	28/95 (29.5)	0.127
Multiple pregnancy	23/95 (24.2)	15/95 (15.8)	0.204
Antenatal steroids, n/total (%)	57/94 (60.6)	56/89 (62.9)	0.763
Clear amniotic fluid, n/total (%)	80/86 (93.0)	78/91 (85.7)	0.147
Male sex, n/total (%)	42/95 (44.2)	50/95 (52.6)	0.310
APGAR Score at 5min, mean \pm SD	8.4 \pm 1.0	8.5 \pm 1.1	0.842
Mother education, # of years, mean \pm SD	11.5 \pm 2.8	12.0 \pm 2.3	0.193
Fathers education, # of years, mean \pm SD	12.5 \pm 2.5	12.0 \pm 2.3	0.164
Total # of household members, mean \pm SD (range)	4.5 \pm 2.6 (2 – 15)	4.4 \pm 2.7 (2 – 16)	0.798
Hospital enrollee distribution, n/total (%)			0.788
Cayetano	13/95 (13.7)	15/95 (15.8)	

Almenara	28/95 (29.5)	24/95 (25.3)	
Sabogal	54/95 (56.8)	56/95 (59.0)	
Risk factors for late-onset sepsis and nutritional characteristics (first month of life or until discharge or withdrawal)			
Duration of hospitalization in days, median (range)	16 (3 – 31)	20 (3 – 32)	0.324
Duration of stay in NICU in days, mean \pm SD (range)	7.3 \pm 9.2 (0 – 30)	7.9 \pm 9.5 (0 – 29)	0.659
Use of TPN in days, mean \pm SD	3.3 \pm 5.4	3.0 \pm 4.9	0.715
Use of catheters in days, mean \pm SD	12.9 \pm 9.4	14.8 \pm 9.6	0.179
Umbilical catheter positioned	1.4 \pm 3.2	1.4 \pm 3.1	0.964
Assisted ventilation in days, mean \pm SD	3.8 \pm 7.1	4.6 \pm 8.1	0.490
Supplemental O ₂ (nasal canula, hood, CPAP)	3.1 \pm 6.1	3.5 \pm 6.6	0.641
Medication, days treated, mean \pm SD			
H ₂ Blockers	0.5 \pm 1.8	0.5 \pm 1.5	0.966
Vasopressors and inotropes	0.2 \pm 0.7	0.4 \pm 2.1	0.437

NICU, neonatal intensive care unit; TPN, total parenteral nutrition; *Lactoferrin: 1547 child-days; Placebo: 1697 child-days of observation.